Abstract:Background and objectives: Angiotensin-converting enzyme (ACE) probably influences the fibrinolytic system at a central point by converting angiotensin I to angiotensin II, which increases plasminogen activator inhibitor-1 (PAI-1) activity. This effect appears to be mediated in humans via the angiotensin II type 1 (AT(1)) receptor. The objective of this study was to evaluate, in patients with mild to moderate hypertension, the change in tissue plasminogen activator (t-PA) and PAI-1 plasma levels after treatment with an AT(1)-receptor blocker (losartan 50 mg/day) or an ACE inhibitor (delapril 60 mg/day). Patients and methods: 30 hypertensive patients and 15 controls were enrolled. Essential hypertension was established by a medical history, physical examination and the absence of clinical findings suggestive of a secondary form of hypertension. Preliminary investigations, routine biochemical tests (including clearance of creatinine and oral glucose tolerance test), chest x-ray, standard and 24-hour ECG monitoring, M- and B-mode echocardiography and fundus oculi examinations were performed. No patients had previously received ACE inhibitors or AT(1)-receptor blockers. After a 14-day run-in period with placebo, patients were randomised in a double-blind fashion into two groups: 15 patients were randomised to losartan 50 mg/day (group 1), 15 patients were randomised to delapril 60 mg/day (group 2), and 15 healthy subjects were used as controls (group 3). Plasma PAI-1 and t-PA antigen were determined by enzyme-linked immunosorbent assay and a photometric method at the end of the run-in period and after 6 months of treatment. Results: There were no significant differences among the three groups regarding age, sex, body mass index and smoking. After 6 months, both groups of patients showed a reduction in blood pressure values. The losartan group did not demonstrate significant changes in PAI-1 levels (96.52 +/- 23.73 and 99.89 +/- 22.18 mug/L, pre- and post-treatment, respectively) or in t-PA antigen levels (26.17 +/- 6.18 and 27.32 +/- 5.91 mug/L, pre- and post-treatment, respectively). The delapril group showed no significant changes in PAI-1 levels (97.73 +/- 25.75 and 86.12 +/- 13.12 mug/L, pre- and post-treatment, respectively), but did show a statistically significant difference (p < 0.005) in t-PA antigen levels (25.71 +/- 6.40 and 32.24 +/- 5.31 mug/L, pre- and post-treatment, respectively). The losartan group demonstrated significantly higher post-treatment PAI-1 values than the delapril group (p = 0.048). Conclusion: The study showed that losartan does not affect fibrinolytic parameters, while delapril resulted in an insignificant reduction in PAI-1 and a significant increase in t-PA levels. Further studies are clearly required in order to establish whether these different effects on the fibrinolytic system between ACE inhibitors and AT(1)-receptor blockers may have clinical relevance.

The Effects of ACE Inhibitor and Angiotensin II Receptor Antagoniston Atrial Natriuretic Factor and Renin-angiotensin Systemin Patients' Plasma with Chronic Renal Failure

[Effects of Angiotensin Converting Enzyme Inhibitor on the Expression of Angiotensin Converting Enzyme 2 in Atrium of Patients with Atrial Fibrillation].

Effect of angiotensin converting enzyme inhibitor and angiotensin Ⅱ receptor blocker on renin-angiotensin system in patients with chronic kidney disease

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes

Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study

Effect of Angiotensin-Converting Enzyme Inhibitor on Renal Function in Patients with Unilateral Atherosclerotic Renovascular Disease

Comparison of the Efficacy and Safety of Sacubitril/Valsartan and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients With Reduced Ejection Fraction Combined With Moderate-to-Severe Chronic Kidney Disease

Effects of combination of irbesartan and perindopril on calcineurin expression and sarcoplasmic reticulum Ca 2+ -ATPase activity in rat cardiac pressure-overload hypertrophy

The Effect of Fosinopril on Plasma Endothelin-1 and Calcitonin Gene-Related Peptide Levels in Patients with Chronic Heart Failure

The Renal Protective Effects of Angiotensin Ⅱ Type Ⅰ Receptor Antagonist and Angiotensin- Converting Enzyme Inhibitor and Their Influences on Intrarenal Renin- Angiotensin System

Effects of losartan and delapril on the fibrinolytic system in patients with mild to moderate hypertension

The Effect of Angiotensin Ⅱ Receptor Blocker on Renin-Angiotensin System in Chronic Kidney Disease Patients

The influence of the daily salt-intake on the antihypertensive action and atrial natriuretic peptide level in patietns with angiotensin receptor neprilysin inhibition

The Effect of Angiotensin II Receptor Blocker on Renin-Angiotensin System in Chronic Kidney Disease Patients

Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor.

Effects of Angiotensin 1-7 and Mas Receptor Agonist on Renal System in a Rat Model of Heart Failure

Prevention of Atrial Fibrillation with Renin-Angiotensin System Inhibitors on Essential Hypertensive Patients: a Meta-Analysis of Randomized Controlled Trials

Efficacy of Sacubitril-Valsartan on Survival and Cardiac Remodeling in Hypotensive Heart Failure With Reduced Ejection Fraction: A Multicenter Study

Influence of Different Inhibitors of Renin-Angiotensin-aldosterone Systems on Peripheral Angiotensin Ⅱ Type 1 Receptor and Its Antibodies in Renovascular Hypertension Rats

PS-C19-9: CLINICAL EFFECTS OF ARNI (SACUBITRIL/VALSARTAN) IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH HYPERTENSION

Investigation of the efficacy of beta-blockers and reninangiotensin-aldosterone system inhibitors in chronic heart failure with preserved ejection fraction